| 0.0085 0.003 (63.46%) | 04-24 10:55 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.1  |
1-year : | 1.29 |
| Resists | First : | 0.94 |
Second : | 1.1 |
| Pivot price | 0.72 |
|||
| Supports | First : | 0.64 |
Second : | 0.46 |
| MAs | MA(5) : | 0.7 |
MA(20) : | 0.71 |
| MA(100) : | 1.24  |
MA(250) : | 5.81 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 75.6 |
D(3) : | 54.4 |
| RSI | RSI(14): 53.4 |
|||
| 52-week | High : | 15 | Low : | 0.46 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PKBO ] has closed below upper band by 32.6%. Bollinger Bands are 66.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 77 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.95 - 0.95 | 0.95 - 0.96 |
| Low: | 0.79 - 0.79 | 0.79 - 0.8 |
| Close: | 0.79 - 0.8 | 0.8 - 0.81 |
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.
Tue, 05 Mar 2024
Peak Bio's Strategic Merger with Akari Therapeutics - TipRanks.com - TipRanks
Tue, 05 Mar 2024
Shareholder Alert: Ademi LLP investigates whether Peak Bio Inc. has obtained a Fair Price in its transaction with Akari - Victoria Advocate
Tue, 05 Mar 2024
Biotech firms Akari and Peak Bio announce merger By Investing.com - Investing.com
Tue, 05 Mar 2024
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline ... - GlobeNewswire
Wed, 13 Sep 2023
Insider Buying: Hoyoung Huh Acquires 47,000 Shares of Peak Bio Inc (PKBO) - Yahoo Finance
Fri, 04 Nov 2022
Peak Bio (PKBO) Stock Price, News & Analysis - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 5.78e+006 (%) |
| Held by Institutions | 33.8 (%) |
| Shares Short | 54 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.61e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 327.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 377140 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.87 |
| Dividend | 0 |
| Forward Dividend | 29050 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|